. 1.  Diagnosis and dynamic assessment of persistent/recurrent and metastatic differentiated thyroid cancer (prmDTC) {#s01}
====================================================================================================================

Differentiated thyroid cancer (DTC), including papillary, follicular and Hürthle cell types, accounts for nearly 95% of all thyroid carcinomas. The concept of DTC recurrence or persistence after surgery is still difficult to define due to its indolent nature. The recurrent or persistent tumors in this guideline refer to new lesions or residual tumors found during the follow-up after initial treatments.

. 1.1  Basic principles of diagnosis {#s01.01}
------------------------------------

The role of multidisciplinary team (MDT) should be emphasized during the diagnosis of prmDTC. A task force of specialists with complementary expertise (endocrinology, surgery, nuclear medicine, radiology, pathology, oncology, molecular diagnostics, and epidemiology) should be included in the MDT management of prmDTC. The diagnosis or further managements of prmDTC which may include surgical managment, radioiodine-131 (^131^I) therapy, thyroid stimulating hormone (TSH) suppressive therapy, as well as molecular targeted therapy (or being enrolled in certain clinical trial) or radiation therapy, etc., should be tailored according to comprehensive consideration of MDT.

. 1.2  Diagnostic methods {#s01.02}
-------------------------

Laboratory tests, imaging studies and pathological examinations are recommended in the diagnosis of prmDTC (*[Table 1](#Table1){ref-type="table"}*).

###### 

Diagnostic methods of prmDTC

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Methods                          Level I recommendation                                                                                                                       Level II recommendation
  -------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------
  Laboratory diagnosis             Serum Tg^a^ and TgAb^b^ (2A)                                                                                                                 Tg washout determination (2A)

  Imaging diagnosis                Various image detections are as follows:                                                                                                     

  　Suspected local lesions        Neck ultrasound^c−e^ (2A), contrast CT or contrast MRI^f^ (2A)                                                                               Ultrasound-guided fine needle aspiration cytology (2A), ^131^I-WBS + SPECT/CT^g^ (2A),\
                                                                                                                                                                                ^18^F-FDG PET/CT (2A)

  　Suspected distant metastasis   CT^h^ (2A), ^131^I-WBS + SPECT/CT (2A), MRI^i^ (suspected nervous system involvement) (2A), bone scan^j^ (suspected bone involvement) (2A)   MRI (when organs other than the nervous system are involved) (2A), ^18^F-FDG PET/CT^k^ (2A)

  Pathological diagnosis                                                                                                                                                        

  　Previous pathology results     Confirmation of previous primary lesions                                                                                                     Review previous tissue specimens

  　Present pathology results      General inspection^l^, microscopic examination^m^ of biopsy specimens                                                                        Immunohistochemistry^n^, molecular pathology^o^ (2A)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

. 1.3  Ongoing assessment of response to therapy (*[Table 2](#Table2){ref-type="table"}*) {#s01.03}
-----------------------------------------------------------------------------------------

###### 

Stratification of ongoing assessment of response to therapy

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Stratification                                Definition (serology and imaging meet simultaneously)                                                                                                                                                                                                                                       Level I recommendation   
  ------------------------------------------ -- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------ ------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Excellent response^a^ (ER)                    Suppressive Tg \<0.2 ng/mL or stimulated Tg \<1 ng/mL                                                                                                                                            Negative                                                                                                            Decrease of the intensity and frequency of follow-up and the degree of TSH suppression (1A)

  Indeterminate response^b^ (IDR)               Non-stimulated Tg detectable, but less than 1 ng/mL. Stimulated Tg detectable, but less than 10 ng/mL. Or Tg antibodies stable or declining in the absence of structural or functional disease   Non-specific findings on imaging studies. Or faint uptake in thyroid bed on RAI scanning                            Continuing observation with appropriate serial imaging of the nonspecific lesions and serum Tg monitoring. Nonspecific findings that become suspicious over time can be further evaluated with additional imaging or biopsy (1A)

  Biochemical incomplete response^c^ (BIR)      Suppressed Tg \>1 ng/mL, Stimulated Tg \>10 ng/mL.\                                                                                                                                              Negative                                                                                                            Those with stable or decreasing serum Tg levels may continue TSH suppression therapy and follow-up; patients with elevated serum Tg or TgAb should prompt additional investigations and potentially additional therapies (1A)
                                                Or rising TgAb levels                                                                                                                                                                                                                                                                                                

  Structural incomplete response^d^ (SIR)       Serum Tg or TgAb at any level                                                                                                                                                                    Structural or functional evidence of disease                                                                        Additional treatments or ongoing observation depending on multiple clinicopathologic factors including the size, location, rate of growth, RAI avidity, ^18^FDG avidity, and specific pathology of the structural lesions (1A)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

As the risk of recurrence and cancer-related death in prmDTC may change over time, life long follow-up and periodical surveillance including laboratory and imaging evaluation are needed. Ongoing assessment of response to therapy should be used to guide the long-term surveillance and therapeutic management decision. In this guideline, we adopted the system of response to therapy which was put forward by 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer.

Multiple factors including clinical, biochemical, imaging (structural and functional) and cytopathology findings were taken into comprehensive consideration in this response system to assess the individual response to therapy during follow-up. It has been verified as an objective ongoing evaluation system to reflect the clinical outcomes from both the risk of recurrence and mortality (1). Four categories including excellent response (ER), indeterminate response (IDR), biochemical incomplete response (BIR) and structural incomplete response (SIR) are used to describe clinical outcomes at any time after initial treatment (1).
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. 2.  Multidisciplinary treatment of prmDTC {#s02}
===========================================

. 2.1  Basic principles of treatment {#s02.01}
------------------------------------

Treatment options for prmDTCs usually include surgical resection, ^131^I therapy of lesions that can uptake ^131^I, external beam radiation therapy, active follow-up under L-T4 suppression therapy and other options (e.g., targeted medicines, radiofrequency or ethanol ablation). Among them, surgery should be the first choice for resectable lesions with surgical indications.

. 2.2  Surgical management {#s02.02}
--------------------------

PrmDTCs are commonly seen in clinical practice, approximately 95% of which occur in the neck (1). Since the difficulty and risk of reoperation increase significantly, the risks and benefits of surgery must always be balanced when selecting reoperation. Surgery should be performed by experienced specialists, and frequently even under multidisciplinary collaboration.

### . 2.2.1  Preoperative clinical assessment {#s02.02.01}

Preoperative clinical assessment includes the review of previous treatments, current status of the disease and vital organ function, which are the basis for the decision regarding intervention and extent of revision surgery. Structural lesions are required as a target for a surgical revision approach, therefore, imaging evaluation is of the utmost importance to surgeons to identify and localize the structural lesions (*[Table 3](#Table3){ref-type="table"}*).

###### 

Recommendations of preoperative clinical assessment

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Evaluation\           Level I\                                                                                                            Level II\                                                                    Level III\
  content^a^            recommendation                                                                                                      recommendation                                                               recommendation
  --------------------- ------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------- ----------------
  Clinical data         Preoperative and pathological record review Complications of previous surgery, such as hematoma, infection, etc.\   ---                                                                          ---
                        Physical exam, esp. special signs for recurrent metastases.                                                                                                                                      

  Laboratory tests      Serum Tg, TgAb, see *1.2 Diagnostic methods* (2A) Parathyroid function evaluation: serum calcium and PTH levels     ---                                                                          ---

  Routine examination   Neck ultrasound (2A)\                                                                                               CT angiogram or MR angiogram (MRA) when suspected of vascular involvement\   ---
                        Contrast neck CT or MRI, chest CT, etc. See *1.2 Diagnostic methods* (2A)\                                          ^131^I-WBS + SPECT/CT and\                                                   
                        Assessment of vocal cords movement and recurrent laryngeal nerve function assessment\                               ^18^F-FDG PET/CT if necessary, see *1.2 Diagnostic methods* (2A)             
                        Laryngoscopy, when trachea involvement is suspected.\                                                                                                                                            
                        Esophagoscopy, when esophagus involvement is suspected.                                                                                                                                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### . 2.2.2  Principles of surgical treatment for prmDTC {#s02.02.02}

The timing and extent of surgery are the most important issues which should be considered when the surgical management of prmDTC is decided. In general, the goal of revision surgery should be to try to cure or control the disease, improve survival, and preserve the function of the vital organs as far as possible (*[Table 4](#Table4){ref-type="table"}*).

###### 

Recommendations of surgical treatment principles

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Lesions                                                                Level I\                                                                                                                                                              Level II\                                                                                                                                                                                                                  Level III\
                                                                         recommendation                                                                                                                                                        recommendation                                                                                                                                                                                                             recommendation
  ---------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------
  Cervical lesions without invasion to surrounding vital structures^a^                                                                                                                                                                                                                                                                                                                                                                                                    

  　Central\                                                             Preservation *in situ* or autotransplantation of parathyroid glands^b^ (2A)                                                                                           Active follow-up: lesion \<8 mm in the smallest dimension (2A)\                                                                                                                                                            Ipsilateral central neck dissection in patient without bilateral central compartment involvement (2B)
  　compartment                                                                                                                                                                                                                                Consider reoperation: lesion ≥8 mm in the smallest dimension (2A)\                                                                                                                                                         
                                                                                                                                                                                                                                               Preoperative FNA (2A)\                                                                                                                                                                                                     
                                                                                                                                                                                                                                               Completion of thyroidectomy and standardized central compartment neck dissection (2A)\                                                                                                                                     
                                                                                                                                                                                                                                               Intraoperative Neuromonitoring (IONM) of the recurrent laryngeal nerve^b^ (2A)                                                                                                                                             

  　Lateral\                                                             ---                                                                                                                                                                   Active follow-up: lesion \<10 mm in the smallest dimension (2A)\                                                                                                                                                           ---
  　compartment                                                                                                                                                                                                                                Consider reoperation: lesion ≥10 mm in the smallest dimension (2A)\                                                                                                                                                        
                                                                                                                                                                                                                                               Preoperative FNA (2A)\                                                                                                                                                                                                     
                                                                                                                                                                                                                                               Therapeutic modified radical neck dissection and preservation of vital structures for previously undissected compartments (2A)\                                                                                            
                                                                                                                                                                                                                                               Limited neck dissection (generally includes levels II, III, IV, or 1-2 levels of them) for previously managed compartments, due to extensive scar and unclear anatomy (2A)                                                 

  Cervical lesions with invasion to surrounding vital structures^c^                                                                                                                                                                                                                                                                                                                                                                                                       

  　Recurrent\                                                           Shave the tumor off as much as possible and preserve the nerve in patient without vocal cord paralysis (2A)\                                                          Nerve reinnervation simultaneously at surgery after resection or injury of the nerve, if feasible (2A) Second-look operation with nerve repair for postoperative identification of recurrent laryngeal nerve injury (2A)   ---
  　laryngeal nerve\                                                     Remove lesions and the affected nerve in patient with preoperative vocal cord paralysis or intraoperative finding of complete tumor encapsulation of the nerve (2A)                                                                                                                                                                                                                              
  　involvement^d^                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  　Airway/digestive\                                                    ---                                                                                                                                                                   Consider shaving tumor in patient with no intraluminal tumor invasion (2A)\                                                                                                                                                ---
  　tract (larynx\                                                                                                                                                                                                                             Resection of the lesion and involved organs in patient with intraluminal tumor invasion; If feasible, simultaneous airway/digestive tract repair and reconstruction, otherwise, tracheostomy (2A)\                         
  　trachea/\                                                                                                                                                                                                                                  Palliative surgery, such as tracheostomy or gastrostomy, in patients having asphyxiation or hemoptysis symptoms with unresectable lesions (2A)                                                                             
  　esophagus)\                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  　involvement^e^                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Table 4 (*continued*)                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

References

Scharpf J, Tuttle M, Wong R, et al. Comprehensive management of recurrent thyroid cancer: An American Head and Neck Society consensus statement: AHNS consensus statement. Head Neck 2016;38:1862-9.

Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1-133.

Leenhardt L, Erdogan MF, Hegedus L, et al. 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J 2013;2:147-59.

Tufano RP, Clayman G, Heller KS, et al. Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance. Thyroid 2015;25:15-27.

Urken ML, Milas M, Randolph GW, et al. Management of recurrent and persistent metastatic lymph nodes in well-differentiated thyroid cancer: a multifactorial decision-making guide for the Thyroid Cancer Care Collaborative. Head Neck 2015;37:605-14.

Rondeau G, Fish S, Hann LE, et al. Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. Thyroid 2011;21:845-53.

Clayman GL, Agarwal G, Edeiken BS, et al. Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma. Thyroid 2011;21:1309-16.

Tufano RP, Bishop J, Wu G. Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation. Laryngoscope 2012;122:1634-40.

Merdad M, Eskander A, Kroeker T, et al. Predictors of level II and Vb neck disease in metastatic papillary thyroid cancer. Arch Otolaryngol Head Neck Surg 2012;138:1030-3.

Eskander A, Merdad M, Freeman JL, et al. Pattern of spread to the lateral neck in metastatic well differentiated thyroid cancer: a systematic review and meta-analysis. Thyroid 2013;23:583-92.

Miyauchi A, Kudo T, Miya A, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 2011;21:707-16.

Tumino D, Frasca F, Newbold K. Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer. Front Endocrinol (Lausanne) 2017; 8:312.

Mitchell AL, Gandhi A, Scott-Coombes D, et al. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016;130:S150-S160.

Jiang XQ, Jiang M, Zhong Y, et al. Prevention of the complications in reoperation for thyroid disease. Zhonghua Nei Fen Mi Za Zhi (in Chinese) 2009;3:393-5.

Roh JL, Kim JM, Park CI. Central compartment reoperation for recurrent/persistent differentiated thyroid cancer: patterns of recurrence, morbidity, and prediction of postoperative hypocalcemia. Ann Surg Oncol 2011;18:1312-8.

Ondik MP, Dezfoli S, Lipinski L, et al. Secondary central compartment surgery for thyroid cancer. Laryngoscope 2009;119:1947-50.

Erbil Y, Sari S, Ağcaoğlu O, et al. Radio-guided excision of metastatic lymph nodes in thyroid carcinoma: a safe technique for previously operated neck compartments. World J Surg 2010;34:2581-8.

Randolph GW, Kamani D. Intraoperative neural monitoring in thyroid cancer surgery. Langenbecks Arch Surg 2014;399:199-207.

Chandrasekhar SS, Randolph GW, Seidman MD, et al. Clinical practice guideline: improving voice outcomes after thyroid surgery. Otolaryngol Head Neck Surg 2013;148:S1-37.

Randolph GW, Dralle H, International Intraoperative Neural Monitoring Study Group, et al. Electrophysiologic recurrent laryngeal nerve monitoring during thyroid and parathyroid surgery: international standards guideline statement. Laryngoscope 2011;121 Suppl 1:S1-16.

Committee of thyroid surgeons of the Chinese medical doctor association surgeon branch. Clinical guidelines for neuroelectrophysiological monitoring in thyroid and parathyroid surgery (Chinese version). Zhongguo Shi Yong Wai Ke Za Zhi (in Chinese) 2013;33:470-4.

Wang W, Chen D, Chen S, et al. Laryngeal reinnervation using ansa cervicalis for thyroid surgery-related unilateral vocal fold paralysis: a long-term outcome analysis of 237 cases. PLoS One 2011;6:e19128.

Zheng H, Zhou S, Chen S, et al. Laryngeal reinnervation for unilateral recurrent laryngeal nerve injuries caused by thyroid surgery. Zhonghua Yi Xue Za Zhi (in Chinese) 2002;82:1042-5.

Wang LY, Nixon IJ, Patel SG, et al. Operative management of locally advanced, differentiated thyroid cancer. Surgery 2016;160:738-46.

McCaffrey TV, Bergstralh EJ, Hay ID. Locally invasive papillary thyroid carcinoma: 1940-1990. Head Neck 1994;16:165-72.

Nishida T, Nakao K, Hamaji M, et al. Preservation of recurrent laryngeal nerve invaded by differentiated thyroid cancer. Ann Surg 1997;226:85-91.

Falk SA, McCaffrey TV. Management of the recurrent laryngeal nerve in suspected and proven thyroid cancer. Otolaryngol Head Neck Surg 1995;113:42-8.

Shindo ML, Caruana SM, Kandil E, et al. Management of invasive well-differentiated thyroid cancer: an American Head and Neck Society consensus statement. AHNS consensus statement. Head Neck 2014;36:1379-90.

Yumoto E, Sanuki T, Kumai Y. Immediate recurrent laryngeal nerve reconstruction and vocal outcome. Laryngoscope 2006;116:1657-61.

Thyroid cancer committee of Chinese Society of Clinical Oncology. Chinese consensus on the diagnosis and treatment for recurrent and metastatic differentiated thyroid cancer. Zhongguo Ai Zheng Za Zhi (in Chinese) 2015;25:481-96.

Kebebew E, Clark OH. Locally advanced differentiated thyroid cancer. Surg Oncol 2003;12:91-9.

Lee YS, Chung WY, Chang HS, et al. Treatment of locally advanced thyroid cancer invading the great vessels using a Y-shaped graft bypass. Interact Cardiovasc Thorac Surg 2010;10:1039-41.

Kamizono K, Ejima M, Taura M, et al. Internal jugular vein reconstruction: application of conventional type A and novel type K methods. J Laryngol Otol 2011;125:643-8.

Moneke I, Kaifi JT, Kloeser R, et al. Pulmonary metastasectomy for thyroid cancer as salvage therapy for radioactive iodine-refractory metastases. Eur J Cardiothorac Surg 2018;53:625-30.

Ramadan S, Ugas MA, Berwick RJ, et al. Spinal metastasis in thyroid cancer. Head Neck Oncol 2012;4:39.

McWilliams RR, Giannini C, Hay ID, et al. Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years. Cancer 2003;98:356-62.

. 2.3  ^131^I therapy {#s02.03}
---------------------

^131^I therapy is one of the important adjuvant postoperative treatment modalities for prmDTC patients. It can reduce the risks of tumor recurrence, metastasis and death in high risk population (1,2), and significantly improve the 5- and 10-year survival for high-risk DTC patients with iodine-avid lesions (3-9).

^131^I therapy is recommended in patients with iodine-avid prmDTC lesions, and should be repeated at an interval of 6−12 months as long as the lesions continue to concentrate radioiodine and respond clinically. In addition, cumulative radioiodine activities, balance between benefits and risks, and patient preferences, are relevant to^131^I therapy decision-making. Patients with TSH stimulation and iodine preparation, whose lesions no longer concentrate ^131^I or respond to ^131^I therapy, are identified as radioactive iodine refractory DTC (RAIR-DTC) in four basic ways: 1) the malignant metastatic lesion does not ever concentrate RAI (no uptake outside the thyroid bed at the first therapeutic WBS); 2) the tumor tissue loses the ability to concentrate RAI after previous evidence of RAI-avid disease (in the absence of stable iodine contamination); 3) RAI is concentrated in some lesions but not in others; and 4) disease progresses despite significant concentration of RAI (10).

### . 2.3.1  Clinical assessment before ^131^I therapy {#s02.03.01}

Clinical information, as well as the status exactly before ^131^I therapy should be considered for tailoring the management of prmDTC (*[Table 5](#Table5){ref-type="table"}*). Further surgical consultation should be advised if a patient has lesions which might be amenable to surgery. While in terms of the clinical information, evaluation of the response to previous therapeutics is critical for subsequent ^131^I therapy of prmDTC, for instance, a previous ^131^I unresponsive patient would be unlikely to benefit from another repeated ^131^I therapy.

###### 

Recommendations of pretherapeutic evaluation for initial/further ^131^I therapy in prmDTC patients

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Evaluation content         Level I\                                                                                                                              Level II\                                  Level III\
                             recommendation                                                                                                                        recommendation                             recommendation
  -------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ ----------------
  Clinical information       Evaluate the response and adverse events to previous therapeutics, including surgery, ^131^I therapy, and TSH suppression, etc.^a^\   ---                                        ---
                             Physical examination                                                                                                                                                             

  Laboratory tests           Thyroid hormones, TSH (2A)\                                                                                                           Serum/Urine iodine measurement             ---
                             Tg, TgAb (2A)\                                                                                                                                                                   
                             Complete blood count, hepatic and renal function test                                                                                                                            

  Routine examination        Electrocardiogram (ECG)                                                                                                               Cardiac ultrasound or dynamic ECG          ---

  Imaging examination        Diagnostic ^131^I WBS^b^ (2A)\                                                                                                        Bone scan (2A)\                            ---
                             Cervical ultrasonography (2A) CT (2A)                                                                                                 MRI (2A)\                                  
                                                                                                                                                                   ^18^F-FDG PET/CT (2A)                      

  Pathological examination   ---                                                                                                                                   *BRAF*^V600E^ mutation detection^c^ (2A)   ---
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

References

Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-63.

Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.

Benbassat CA, Mechlis-Frish S, Hirsch D. Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer. World J Surg 2006;30:1088-95.

Schlumberger M, Tubiana M, De Vathaire F, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986;63:960-7.

Ruegemer JJ, Hay ID, Bergstralh EJ, et al. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 1988;67:501-8.

Wood WJ Jr, Singletary SE, Hickey RC. Current results of treatment for distant metastatic well-differentiated thyroid carcinoma. Arch Surg 1989;124:1374-7.

Pacini F, Cetani F, Miccoli P, et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg 1994;18:600-4.

Lin JD, Huang MJ, Juang JH, et al. Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. Thyroid 1999;9:1227-35.

Shoup M, Stojadinovic A, Nissan A, et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 2003;197:191-7.

Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1-133.

Chinese Society of Nuclear Medicine. Clinical guidelines for 131I therapy of differentiated thyroid cancer. Zhonghua He Yi Xue Yu Fen Zi Ying Xiang Za Zhi (in Chinese) 2014;34:264-78.

Professional Committee of Thyroid Cancer, Chinese Society of Clinical Oncology. Consensus on diagnosis and treatment of recurrent and metastatic differentiated thyroid cancer. Zhongguo Ai Zheng Za Zhi (in Chinese) 2015;25:481-96.

Yang K, Wang H, Liang Z, et al. BRAFV600E mutation associated with non-radioiodine-avid status in distant metastatic papillary thyroid carcinoma. Clin Nucl Med 2014;39:675-9.

Yang X, Li J, Li X, et al. TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer. J Nucl Med 2017;58:258-65.

### . 2.3.2  Management of ^131^I therapy for prmDTC {#s02.03.02}

Indications and dose determination of ^131^I therapy for prmDTC are addressed in terms of the sites of metastases (*[Table 6](#Table6){ref-type="table"}*).

###### 

Recommendations for ^131^I administration in prmDTC patients

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Items                                      Recommendation                                                                                                    
  ------------------------------------------ ---------------------------------------------- ------------------------------------------------------------------ ----------------------------------------------
  Indications of ^131^I therapy for prmDTC                                                                                                                     

  　Local lesions                            ---                                            ^131^I therapy (iodine-avid lesions)^a^ (2A)                       ---

  　Lung metastases                          ^131^I therapy (iodine-avid lesions)^b^ (1B)   ---                                                                ---

  　Bone metastases                          ---                                            ^131^I therapy (iodine-avid lesions)^c^ (2A)                       ---

  　Brain metastases                         ---                                            ---                                                                ^131^I therapy (iodine-avid lesions)^d^ (2B)

  　Tg(+)^131^I(−)                           ---                                            ---                                                                Empirical ^131^I therapy^e^

  Preparation for ^131^I therapy                                                                                                                               

  　TSH \>30 mIU/L                           Levothyroxine (L-T4)\                          Liothyronine (L-T3) may be substituted for L-T4 for at least\      ---
                                             withdrawal for at least\                       4 weeks, and then should be withdrawn for at least 2 weeks (2A)\   
                                             2−4 weeks (2A)                                 rhTSH^f^ (2A)                                                      

  　Low iodine diet                          Low iodine diet for at least 2 weeks^g^ (2A)   ---                                                                ---

  Table 6 (*continued*)                                                                                                                                        
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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. 2.4  TSH suppression therapy {#s02.04}
------------------------------

### . 2.4.1  Strategy for TSH suppression therapy {#s02.04.01}

For prmDTC that expresses TSH receptor, TSH suppression therapy is important in postoperative management of differentiated thyroid cancer. It has been realized the optimal degree of TSH suppression varies. An individually tailored approach to deciding TSH targets in prmDTC patients considering risk of side effects has been raised (*[Table 7](#Table7){ref-type="table"}*).

###### 

Strategy for TSH suppression therapy

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Treatment period                Level I recommendation                                                                               Level II recommendation
  ------------------------------- ---------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
  Whole-course^a^                 Applicable patients: prmDTC expresses TSH receptor (category 1A)\                                    ---\
                                  First-line medication: oral L-T4 agents (category 1A)\                                               \
                                  Starting L-T4 dose: based on patient\'s age and co-existing diseases\                                \
                                  Final L-T4 dose: titrated according to patient's TSH goal and results of monitoring (category 1A)\   \
                                  Check TSH every 4−6 weeks during the L-T4 dose adjustment (category 1A)                              \
                                                                                                                                       \
                                                                                                                                       \
                                                                                                                                       Extend intervals of TSH monitor to 3−6 months once TSH reaches the goal (category 2A)

  Initial period^b^               TSH target based on risks of TSH suppression therapy (category 1A)\                                  ---
                                  -Low risk: \<0.1 mU/L (category 2A)\                                                                 
                                  -High risk: If tolerated, \<0.1 mU/L to lower normal limit (category 2A)                             

  Long-term follow-up period^c^   TSH target based on dynamic assessments\                                                             -ER: lower normal limit to 2.0 mU/L (category 2A)\
                                  (category 2A)                                                                                        -IDR: around the lower normal limit of TSH (category 2A)\
                                                                                                                                       -BIR: 0.1 mU/L to lower normal limit; If risk of side effects of TSH suppression is low, \<0.1 mU/L (category 2A)\
                                                                                                                                       -SIR: If tolerated, \<0.1 mU/L\
                                                                                                                                       (category 2A)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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### . 2.4.2  Management of adverse effects of TSH suppression therapy {#s02.04.02}

When TSH has to be suppressed below the normal range (i.e. subclinical thyrotoxicosis) for a long period, especially below 0.1 mU/L, it may cause adverse effects (AEs) (*[Table 8](#Table8){ref-type="table"}*).

###### 

Management of adverse effects of TSH suppression therapy

  Adverse events (AE)     Level I recommendation                                                                               Level II recommendation
  ----------------------- ---------------------------------------------------------------------------------------------------- -------------------------
  All AE^a^               Set individualized TSH targets, monitor AEs and adjust L-T4 doses in a timely manner (1A)            ---
  Cardiovascular AE^b^    Baseline cardiovascular assessment (2A), β blockers (2A)                                             ---
  Skeletal system AE^c^   Baseline skeletal assessment (2A), primary prevention of osteoporosis (OP); anti-OP treatment (2A)   ---
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. 2.5  External beam radiation therapy {#s02.05}
--------------------------------------

External beam radiation therapy (EBRT) is an effictive and safe local therapy with benefit to local control and palliative care for prmDTC. EBRT, stereotactic radiation therapy (SBRT) and other local therapies can be used for symptomatic, weight-bearing, key site metastasis, and oligo-metastasis (*[Table 9](#Table9){ref-type="table"}*).

###### 

Recommendation of external beam radiation therapy for prmDTC

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Lesions                   Level I recommendation      Level II recommendation                                                         Level III recommendation
  ------------------------- --------------------------- ------------------------------------------------------------------------------- ----------------------------------------------------
  Local recurrent lesions   ---                         EBRT (unresectable local recurrent lesions)^a,b^ (2A)                           ---

  Metastatic lesions        ---                         ---                                                                             ---

  　Lung metastases         ---                         EBRT/SBRT (single or oligo-metastasis)^c^ (2A)                                  EBRT/SBRT (selective for multiple metastases) (2B)

  　Bone metastases         ---                         EBRT/SBRT (symptomatic or weight bearing bones)^d^ (2A)                         ---

  　Brain metastases        EBRT/SBRT (single or\       EBRT/SBRT (multiple metastases) (2B)                                            ---
                            oligo-metastasis)^e^ (2A)                                                                                   

  　Other metastases        ---                         EBRT/SBRT (non-iodine-avid disease, palliative relief of local symptoms) (2B)   ---
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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. 2.6  Systemic therapy {#s02.06}
-----------------------

Close follow-up is recommended in patients identified as RAIR-DTC. The degree of disease progression should be factored into treatment decisions. Systemic therapy, including chemotherapy and molecular targeted therapy, should be considered in RAIR-DTC patients with rapidly progressive and/or symptomatic disease. Potential benefits and risks of systemic therapy should be thoroughly balanced in the candidates (*[Table 10](#Table10){ref-type="table"}*, *[11](#Table11){ref-type="table"}*).

###### 

Stratified recommendations for potential systemic therapy in RAI-refractory prmDTC patients

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Stratification^a^                          Level I\                                                                                          Level II\                                                                                     Level III\
                                             recommendation                                                                                    recommendation                                                                                recommendation
  ------------------------------------------ ------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- ----------------
  Asymptomatic, stable or slow progression   Regular follow-up (2A)                                                                            Participation in clinical trials^d^ (2A)                                                      ---

  Symptomatic or rapid progression           Sorafenib^b,c^ (1)                                                                                Adriamycin^e^ (2A); Participation in clinical trials (2A)                                     ---

  Termination of targeted therapy            Tumor response evaluated to be progressive disease (PD) according to RECIST (1A)\                 Tg continues to rise or fail to decrease without disease remission according to RECIST (2A)   ---
                                             Serious drug-related adverse reactions that cannot be tolerated for continued treatment^f^ (1A)                                                                                                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Efficacy of molecular targeted drugs for thyroid cancer therapeutics

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medicines       Pathological type   Experimental design   Number of cases       ORR                Median PFS (month)   References
  --------------- ------------------- --------------------- --------------------- ------------------ -------------------- -------------------------------------------------------
  Sorafenib       RAIR-DTC            Phase III\            207 SOR, 210 PLC      12.2% *vs*. 0.5%   10.8 *vs*. 5.8       Lancet 2014; 384:319-28.
                                      RCT *vs*. PLC                                                                       

  Lenvatinib^a^   RAIR-DTC            Phase III\            261 LEN, 131 PLC      64.8% *vs*. 1.5%   18.3 *vs*. 3.6       New England journal of medicine 2015;372: 621-30.
                                      RCT *vs*. PLC                                                                       

  Apatinib^b^     RAIR-DTC            Phase II              10                    90%                NR                   Oncotarget 2017;8:42252-61.

  Pazopanib       RAIR-DTC            Phase II              37                    49%                11.7                 The Lancet Oncology 2010;11:962-72.

  Sunitinib       RAIR-DTC            Phase II              23                    26%                8                    European Journal of Endocrinology 2016;174:373-80.

                  RAIR-DTC/MTC        Phase II              27 RAIR-DTC, 7 MTC    31%                NR                   Clinical cancer research 2010;16:5260-8.

  Axitinib        RAIR-DTC/MTC        Phase II              45 RAIR-DTC, 11 MTC   30%                16.1                 Cancer 2014;120:2694-703.

                  RAIR-DTC/MTC        Phase II              45 RAIR-DTC, 6 MTC    35%                15                   Cancer Chemotherapy and Pharmacology 2014;74:1261-70.

  Vandetanib      RAIR-DTC            Phase II\             72 VAN, 73 PLC        8% *vs*. 5%        11.1 *vs*. 5.9       The Lancet Oncology 2012;13:897-905.
                                      RCT *vs*. PLC                                                                       

  Cabozantinib    RAIR-DTC            Phase I               15                    53%                NE                   Thyroid 2014;24:1508-14.
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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